APP and Alzheimer disease: We recognize that APP 5’UTR is an mRNA target for translation blockers such as the anti-cholinesterase phenserine and its enantiomer posiphen, each being of sufficient interest to merit clinical trials for their action as anti-amyloid agents in older subjects at risk for AD [24].